Recent Innovations in Antibody-Mediated, Targeted Particulate Nanotechnology and Implications for Advanced Visualisation and Drug Delivery

Francois      Fay; Christopher      J. Scott; Paul      A. McCarron

doi:10.2174/157341310793348641

Abstract

Research into the targeting of drug substances to a specific disease site has enjoyed sustained activity for many decades. The reason for such fervent activity is the considerable clinical advantages that can be gained when the delivery system plays a pivotal role in determining where the drug is deposited. When compared to conventional formulations where no such control exists, such as parenteral and oral systems, the sophisticated targeting device can reduce side effects and limit collateral damage to surrounding normal tissue. No more so is this important than in the area of oncology when dose-limiting side effects are often encountered as an ever present difficulty. In this review, the types of colloidal carrier commonly used in targeted drug delivery are discussed, such as gold and polymeric colloids. In particular, the process of attaching targeting capabilities is considered, with reference to antibody technologies used as the targeting motifs. Nanotechnology has brought together a means to carry both a drug and targeting ligand in self-contained constructs and their applications to both clinical therapy and diagnosis are discussed.

Keywords: Nanoparticles, antibody, cell targeting, internalization, oncology, NP, rheumatoid arthritis, X-ray radiography, magnetic resonance imaging, optoacoustic tomography, light spectroscopy, SPR, PTT, FDA, pseudomonas aeruginosa, Dendrimers, QD, PLA, PGA, PLGA, EPR, hyaluronic acid, HAMA, pH, Fab region, PEG, Thiols, DTT, Biotin, Fc, ELISA, HER2, EGFR, macrophage, Leukocyte, HeLa, trastuzumab, Ab-NP conjugates